Selcia Ltd.. (1/25/18). "Press Release: Selcia Joins Eurofins Group". Ongar.

	Organisation	Selcia Ltd.
	Group	Eurofins (Group)
	Organisation 2	Eurofins Scientific SE (EUFI.PA)
	Group	Eurofins (Group)
	Product	radiolabeling service
	Product 2	drug discovery services
	Index term	Selcia–Eurofins: investment, 201801 acquisition of Selcia Ltd by Eurofins
	Person	Kuegler, Klaus (Eurofins 201801 SVP Agroscience Services Group)
	Person 2	Cornell, Clive (Selcia 201801 COO)

Selcia Limited, a leading global provider of custom radiolabelling and integrated drug discovery services, announces that it has been acquired by Eurofins Scientific (EUFI.PA), a global leader in analytical testing and pharma discovery services.

The acquisition of Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery services markets, both exciting new business streams for Eurofins offering significant growth potential.

Klaus Kuegler, Senior Vice President of Eurofins Agroscience Services Group, comments, “We are extremely pleased to welcome Selcia to the Eurofins Group. Selcia’s focus on quality and world leading carbon-14 (14C) radiolabelling capabilities, including GLP analytical and GMP API manufacturing, fills a strategic gap in Eurofins’ global offering in the highly attractive pharmaceutical and agroscience testing markets. In addition, Selcia provides Eurofins with integrated drug discovery services including medicinal chemistry and a unique peptidyl prolyl isomerase (PPIase) inhibitor screening platform. We look forward to supporting Selcia’s growth by providing access to the full range of services and capabilities of the Eurofins Group.”

Clive Cornell, Chief Operating Officer at Selcia, adds, “We are excited to become an integral part of the Eurofins Group. The acquisition will help Selcia invest and grow to meet the increasing global demand for high quality, 14C radiolabelled compounds. Importantly Selcia will continue to independently foster relationships with new and existing customers as well as with Eurofins’ worldwide network of laboratories. The acquisition enables Eurofins Pharma Discovery Services to provide a more comprehensive offering of integrated drug discovery services including innovative hit to lead and lead optimisation medicinal chemistry, assay development and screening.”

Selcia acknowledges the help and support of InterPharmaLink, Basel, in facilitating the transaction.

Ends

About Selcia

Selcia is an established contract research organisation (CRO) operating from modern facilities in Ongar, Essex, UK and providing services to many customers in the pharmaceutical, agrochemical, biotechnology, life sciences and chemical industries. Its custom 14C radiolabeled compounds are used to support a wide range of critical regulatory and research studies across many disciplines such as environmental fate, dermal penetration, drug metabolism, human mass balance and absolute bioavailability. Its drug discovery services business has a track record of delivering preclinical development candidates and provides Eurofins with access to innovative capabilities that complement and integrate with their existing, comprehensive pharma discovery Services. www.selcia.com

About Eurofins

Eurofins Scientific, through its subsidiaries is a world leader in food, environment and pharmaceutical products testing and is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Selcia’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Selcia disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

Record changed: 2023-06-05